New agents for the treatment of acute myelogenous leukemia. Focus on topotecan and retinoids

Leukemia

Volumn 12, Issue SUPPL. 1, 1998, Pages

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ara C; Karyotype; Retinoid; Topotecan

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LISOFYLLINE; MONOCLONAL ANTIBODY; RETINOIC ACID; RETINOID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CONFERENCE PAPER; CYTOGENETICS; DRUG EFFICACY; HUMAN; KARYOTYPE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REMISSION; SURVIVAL TIME;

EID: 0031757090     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90:2969-2977.